GSK’s Ellipta™ portfolio includes five different combination therapies, collectively worth $3bn in 2019, and growing at 13% year-on-year. Major products go off patent from 2025. Device patents last into the 2030s. Generic challengers need a compelling 505(j)-able device to access this huge market.
TTP has designed more than thirty inhalation devices since 1987 and, recognising this need, has applied its product design, reliability engineering, and aerosol science expertise to create Ergo - an Ellipta true generic device, available now to license.
Ergo uses standard “Diskus™” blister strips, easing adoption, and the in vitro ISM and DDU are matches for both formulations at all FDA flow rates. Multiple user studies have ensured equivalence, and extensive patent insight gives confidence of freedom to operate. Ergo itself is protected by multiple granted and pending patents.
Being a TTP device, robust, scalable design come as standard.
Contact us to find out more about Ergo's user-tested usability and RLD-matching flexible drug delivery performance, and how it can enable your generic inhalation strategy.